New phase 3 data show meaningful improvement in antibody-negative myasthenia gravis, for which treatment options are limited ...

Takenobu Y, Kikuchi T, Ishikawa D, et al. Rozanolixizumab as rescue therapy in triple seronegative refractory generalized ...

The ongoing EPIC clinical trial is the first randomized head-to-head comparison of two neonatal Fc receptor (FcRn)-targeting ...

Thermo Fisher Scientific Inc., the world leader in serving science, today announced the enrollment of the first patient in the new PPD(TM) CorEvitas(TM) Myasthenia Gravis (MG) Registry. This ...

Two open-label extension studies show that the FcRn blocker nipocalimab has durable efficacy and sustained symptom control ...

SAN FRANCISCO -- Investigational gefurulimab met its primary efficacy endpoint in adults with anti-acetylcholine receptor (AChR) antibody-positive generalized myasthenia gravis (MG), topline data from ...

Nipocalimab shows promise in treating myasthenia gravis in children, with ongoing trials revealing safety and efficacy ...

Kyverna Therapeutics (KYTX) is rated a strong buy with promising KYV-101 Phase 2 data and near-term catalysts. Read here for ...

Myasthenia gravis is a chronic autoimmune disorder, where your own immune system disrupts the communication between nerves ...

Despite growing competition and an expanding array of differentiated dosing profiles designed to enhance patient convenience, retention on first-line biologics remains exceptionally high at 90%, ...

Results from the phase III VIBRANCE-MG study presented at the American Association of Neuromuscular & Electrodiagnostic Medicine annual meeting showed that nipocalimab (Imaavy) was safe and ...

Despite the recent approval of targeted biologics that can significantly improve quality of life, Canadians living with Myasthenia Gravis continue to face unjust policy barriers.